Abstract: Provided herein are piperidine dione compounds having the following structure: (I) wherein Y, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: (I) wherein RN, Y, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, A, A?, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, A, A?, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Abstract: Methods of treating conditions for which S1P-mediated neuroprotection is medically indicated, comprising administering to a subject in need thereof an agonist of the sphingosine 1-phosphate receptor (S1P receptor); such as a compound having the following structure (See Formula 1): or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.

Abstract: Methods of treating conditions for which S1P-mediated neuroprotection is medically indicated, comprising administering to a subject in need thereof an agonist of the sphingosine 1-phosphate receptor (S1P receptor); such as a compound having the following structure (See Formula 1): or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.

Abstract: Compounds resulting from the administration of torcetrapib to a mammal, and the use of such compounds as an indicator or biomarker to the presence or exposure of torcetrapib in the plasma of a mammal including humans. The invention is also directed to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)-cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycerides.